



## Fosun Newsletter

January 2017



## Stock Information (As at 31 January 2017)

Stock Price.....HKD 11.96  
 52-week range.....HKD 9.37-12.52  
 Total shares (mn shares)..... 8,590.68  
 Market Value (HKD bn).....102.74

Integrated Finance (Wealth)  
Insurance

Gross Premium Written (thousand RMB)	Yong'an P&C Insurance	Pramerica Fosun Life Insurance
November 2016	622,501	13,938
December 2016	500,873	9,464
<b>Jan-Dec 2016</b>	<b>9,101,800</b>	<b>116,045</b>

Note: Fosun Insurance Portugal, Peak Re, Ironshore and MIG do not announce the monthly gross premium written.

Industrial Operations  
Forte

	Attributable Sales GFA (sq.m.)	Attributable Sales Amount (RMB mn)
December 2016	156,488	2,320
<b>Jan-Dec 2016</b>	<b>1,243,226</b>	<b>17,917</b>
January 2017	53,274	837

## Enter Advanced Immunotherapy Domain, Fosun Pharma and Kite Pharma Strategic Cooperation Officially Launched

On 11 January 2017, Fosun Pharma announced that it set up Sino-foreign joint venture with Kite Pharma through its wholly-owned subsidiary, introducing the leading cancer treatment technology and blockbuster products into China and providing international leading treatment for cancer patients. The wholly-owned subsidiary of Fosun Pharma plans to invest no more than US\$80 million to establish the joint venture in Shanghai. Through the cooperation, the resource advantage of both companies will be utilized to build China's leading platform of t-cell immunity in the treatment industry. The cooperation will make full use of the industry experience and operation capability of Fosun Pharma and the leading research capabilities of Kite Pharma in t-cell therapy product.

Kite Pharma is a global leader in research and development of t-cell immunotherapy. Its flagship product KTE-C19 is a t-cell therapy products under research for the treatment of b-cell lymphoma and leukemia, which is the first product that this collaboration intends to introduce. According to medium-term results of clinical research, the remission rates of KTE-C19 for patients with relapsed/refractory Lymphoma has greatly increased to 39% compared with 8% of conventional salvage treatment. The duration of remission of patients who treated earliest has reached 22 months, and those patients are under sustained remission close to cure.

## Investment

### **Fosun Property Further Expands Its Business in Europe, Completes Acquisition of Commercial Office Building Estrella in Frankfurt**

On 19 January 2017, Fosun Property announced the acquisition of Estrella, a Grade-A commercial office building, in Frankfurt via Resolution Property. This is Fosun Property's first step into the German property market. Estrella, a commercial office building built in 2000 with a floor area of approximately 30,000 square meters, used to be the trading centre for Commerzbank, the second largest commercial bank in Germany. Estrella is located at the gateway to Frankfurt's City West district, adjacent to Frankfurt International Exhibition Centre, the third largest convention centre in the world. Upon completion of the acquisition, Fosun Property will make the best of Resolution Property's successful development experience, such as Alphabeta in the UK, to renovate and reposition Estrella into a space with versatile use and a TMT style Grade-A office, gathering more financial, creative, media, technology and other modern enterprises, and establish another creative office landmark project for Frankfurt.

### **Investment in the Respiratory Medicine Business, Fosun Pharma Completes Acquisition of European Leading Ventilator Equipment - Breas**

On 26 January 2017, Fosun Pharma announced that Fosun Pharma and Fosun International, jointly set up a joint venture in Sweden, and completed the acquisition of 80% shares of Goldcup with not more than 90 million US dollars through share transfer and subscription. Goldcup was founded in Sweden in 2017 and is a new company established for the reorganization of the transaction. Prior to this transaction, PBM transferred all equipment-related companies of Breas to Goldcup. Headquartered in Gothenburg, Sweden, Breas is a professional medical equipment company specializing in R&D, manufacture and sale of medical equipment for sleep apnea and chronic obstructive pulmonary disease. It has a high quality and high performance ventilator brand in Europe and has established mature distribution network in Europe and the United States. The ventilator is mainly used for the treatment of chronic obstructive pulmonary disease and sleep apnea syndrome. The transaction is conducive to enhance the Fosun Pharma's R&D strength of medical equipment, enrich the medical device product line, and help Fosun Pharma establish an integrated medical devices operating platform covering the global online and offline markets.